Recent results with reduced-intensity allogeneic transplantation for Hodkin lymphoma (HL).
| Author . | n . | Prior ASCT . | Prior regimens (median) . | TRM, % (time point) . | PFS, % (time point) . | OS, % (time point) . |
|---|---|---|---|---|---|---|
| Abbreviations: n, number of allogeneic transplants; ASCT, autologous stem cell transplant; TRM, transplant-related mortality; PFS, progression-free survival; OS, overall survival | ||||||
| Peggs51 | 49 | 44 | 5 | 16 (2 y) | 32 (4 y) | 56 (4 y) |
| Sureda52 | 89 | 55 | 85% ≥ 3 | 23 (1 y) | 18 (3 y) | 35 (3 y) |
| Alderlini53 | 40 | 30 | 5 | 22 (18 m) | 55 (18 m) | 61 (18 m) |
| Armand54 | 36 | 34 | 4 | 15 (3 y) | 22 (3 y) | 56 (3 y) |
| Alvarez55 | 40 | 29 | 55% ≥ 3 | 25 (1 y) | 32 (2 y) | 48 (2 y) |
| Author . | n . | Prior ASCT . | Prior regimens (median) . | TRM, % (time point) . | PFS, % (time point) . | OS, % (time point) . |
|---|---|---|---|---|---|---|
| Abbreviations: n, number of allogeneic transplants; ASCT, autologous stem cell transplant; TRM, transplant-related mortality; PFS, progression-free survival; OS, overall survival | ||||||
| Peggs51 | 49 | 44 | 5 | 16 (2 y) | 32 (4 y) | 56 (4 y) |
| Sureda52 | 89 | 55 | 85% ≥ 3 | 23 (1 y) | 18 (3 y) | 35 (3 y) |
| Alderlini53 | 40 | 30 | 5 | 22 (18 m) | 55 (18 m) | 61 (18 m) |
| Armand54 | 36 | 34 | 4 | 15 (3 y) | 22 (3 y) | 56 (3 y) |
| Alvarez55 | 40 | 29 | 55% ≥ 3 | 25 (1 y) | 32 (2 y) | 48 (2 y) |